TITLE

The Industry

PUB. DATE
February 2009
SOURCE
Pharmaceutical Representative;Feb2009, Vol. 39 Issue 2, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. Spectrum Pharmaceuticals Inc. and Cell Therapeutics Inc. have agreed to develop Zevalin through the joint venture RIT Oncology. Valeant Pharmaceuticals International is acquiring Dow Pharmaceutical Sciences Inc. for $285 million. Biopharmaceutical company Archemix Corp. will merge with cardiovascular drug company Nitromed.
ACCESSION #
36406405

 

Related Articles

  • VALEANT TO ACQUIRE DOW PHARMACEUTICAL SCIENCES FOR $285 MIL.  // Biotech Financial Reports;Jan2009, Vol. 16 Issue 1, p7 

    The article reports on the merger of Valeant Pharmaceuticals International and Dow Pharmaceutical Sciences Inc. Valeant signed an agreement in acquiring Dow worth $285 million including other pharmaceutical and biotechnology companies. The approval of the agreement was done by the board of...

  • EXECUTIVE SUMMARY.  // Orange County Business Journal;12/15/2008, Vol. 31 Issue 50, p4 

    The article offers news briefs related to business in California. Drug maker Valeant Pharmaceuticals International will purchase Dow Pharmaceutical Sciences Inc. The shares of chipmaker Broadcom Corp. slumped on the second week of December 2008 after it lowered its outlook for the quarter....

  • Valeant Aims for $500M in Skin Care Sales. Reed, Vita // Orange County Business Journal;11/16/2009, Vol. 32 Issue 46, p3 

    The article reports on the acquisition of several skin drug companies by Valeant Pharmaceuticals International in Aliso Viejo, California. Since Valeant chief executive J. Michael Pearson took over in 2008, the drug maker made a variety of acquisitions. During the year, its skin drug deals...

  • Valeant Expands Dermatology Business with $285M Deal.  // BioWorld Today;12/11/2008, Vol. 19 Issue 240, p1 

    The article reports on the purchase of Dow Pharmaceutical Sciences Inc., a privately held company that specializes in development of topical products, by Valeant Pharmaceuticals for $285 million. The deal gives Valeant an acne product approved by the U.S. Food and Drug Administration (FDA) and a...

  • Allergan Passes Pfizer Acquisition Test, Analyst Says. Reed, Vita // Orange County Business Journal;3/24/2008, Vol. 31 Issue 12, p12 

    The article reports developments concerning the California health care industry. Analyst Catherine Arnold stated that Allergan Inc. passed the testing process and the acquisition standards of Pfizer Inc. Spectrum Pharmaceuticals Inc. received approval on its injectable levoleucovorin cancer drug...

  • NEWS FOCUS.  // Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p7 

    The article offers news briefs related to the pharmaceutical industry in the U.S. Cephalon Inc. has signed an agreement with Alba Therapeutics Corp. to purchase all assets relating to larazotide acetate. Arena Pharmaceuticals Inc. will cut its workforce by 25%. Valeant Pharmaceuticals...

  • I&I News Round-Up.  // PharmaWatch: Monthly Review;Apr2010, Vol. 9 Issue 4, p16 

    The article offers news briefs related to pharmaceutical industry in the U.S. Valeant Pharmaceuticals Inc. has signed an agreement with Spear Pharmaceuticals Inc. for rights to trade Refissa, a topical tretinoin cream. MorphoSys AG and Galapagos have extended their partnership in bone and joint...

  • Other News To Note.  // BioWorld Today;7/18/2011, Vol. 22 Issue 137, p2 

    The article offers medical news briefs. California-based Amgen Inc.'s Xgeva (denosumab) drug for preventing skeletal-related events (RSE) in adults with bone metastases was approved by the European Commission. BioTime Inc. was awarded by the National Institutes of Health of a 10-month 335,900...

  • CORPORATE.  // MondayMorning;1/23/2012, Vol. 20 Issue 4, p2 

    This section offers news briefs on the pharmaceutical industry in the U.S. Merck & Co. has reached a settlement to pay a certain amount to resolve all claims in Canada relating to painkiller Vioxx it withdrew from the market in 2004. Valeant Pharmaceuticals International Inc. raised its offer...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics